Evidence map›Paper›PMID 42105786›Full record

ReviewJournal of immunology research2026

Immunotherapy for Leiomyosarcoma: Current Status and Perspectives.

Haoyue Qi, Hanxi Zhang, Qin Wang, Xiaolu Wang, Limei Min, Yingling Zhou, Baorui Liu, Rutian Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Haoyue QiDepartment of Oncology, Taikang Xianlin Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China, nju.edu.cn.ORCID https://orcid.org/0009-0003-8278-1671
Hanxi ZhangDepartment of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China, nju.edu.cn.
Qin WangDepartment of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China, nju.edu.cn.
Xiaolu WangDepartment of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China, nju.edu.cn.
Limei MinDepartment of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China, nju.edu.cn.
Yingling ZhouDepartment of Oncology, Nanjing Drum Tower Hospital, Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China, njucm.edu.cn.
Baorui LiuDepartment of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China, nju.edu.cn.ORCID https://orcid.org/0000-0002-2539-7732
Rutian LiDepartment of Oncology, Taikang Xianlin Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China, nju.edu.cn.ORCID https://orcid.org/0000-0003-4800-6156

Funding

"333 Project" of Jiangsu Province (2020)2-020Nanjing Drum Tower Hospital 2022-LCYJ-MS-09Nanjing Medical Science and Technique Development Foundation YKK23077National Natural Science Foundation of China 82103687
6 · The paper itself

Abstract

Leiomyosarcoma (LMS), one of the soft-tissue sarcomas (STSs), has a relatively higher risk of distant metastasis. This has resulted in current first-line treatments still failing to deliver satisfactory outcomes, and the current treatment of LMS remains controversial and challenging. Therefore, it is worth thinking about how to guide and decide on the direction of treatment for LMS. In this review, we analyzed the immune microenvironment, gene expression, and molecular landscape of LMS, hinting at future research directions and prospects for LMS. We also analyzed the classical immunotherapy led by immune checkpoint inhibitors (ICIs), individualized immunotherapy such as cell therapy, and gene editing technologies, which bring better effect mechanisms and survival benefits, as well as opportunities and challenges for large-scale clinical applications.

Indexed as

ImmunotherapyLeiomyosarcomaAnimalsHumansImmune Checkpoint InhibitorsTumor MicroenvironmentImmune Checkpoint Inhibitorsimmunotherapyleiomyosarcomasoft-tissue sarcomas (STS)tumor microenvironment

Identifiers

PMID42105786
PMCPMC13157314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.